GTS Securities’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-20,000
Closed -$126K – 4234
2024
Q2
$126K Buy
+20,000
New +$132K ﹤0.01% 3570

Other funds holding IBRX

GTS Securities's IBRX Position: Q3 2026 in Review

GTS Securities sold out of ImmunityBio (IBRX) in Q3 2026, closing a stake of 13,465 shares — an estimated $118K sold.

GTS Securities first reported a position in IBRX in Q1 2024 and held it in 3 quarters. The position peaked at $118K in Q2 2026. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • GTS Securities reported no remaining ImmunityBio position as of Q3 2026 after selling out during the quarter.
  • GTS Securities sold 13,465 ImmunityBio shares in Q3 2026, an estimated $118K.
  • GTS Securities first reported a position in ImmunityBio in Q1 2024 and held it in 3 quarters.
  • GTS Securities's ImmunityBio position peaked at $118K in Q2 2026.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.